FDA — authorised 20 December 2024
- Application: BLA761315
- Marketing authorisation holder: NOVO NORDISK INC
- Local brand name: ALHEMO
- Indication: Injectable — Subcutaneous
- Status: approved
🇺🇸 Alhemo in United States
FDA authorised Alhemo on 20 December 2024
Marketing authorisations
FDA
- Marketing authorisation holder: NOVO NORDISK INC
- Status: approved
Alhemo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Rare Disease approved in United States
Frequently asked questions
Is Alhemo approved in United States?
Yes. FDA authorised it on 20 December 2024; FDA has authorised it.
Who is the marketing authorisation holder for Alhemo in United States?
NOVO NORDISK INC holds the US marketing authorisation.